New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76% of patients on monthly dosing and 86% on biweekly dosing achieved clear or almost clear skin, with 96% reaching significant eczema improvement. The safety profile remains consistent with earlier studies, mostly mild or moderate side effects. This offers patients and doctors more flexible treatment options without compromising effectiveness.
Eli Lilly has become the first healthcare company to reach a $1 trillion market valuation, fueled by strong sales of its weight loss drugs like Mounjaro and Zepbound. The company reported a 55.5% revenue increase year-over-year to $19.8 billion in th...
Eli Lilly's board has declared a dividend of $1.73 per share for the third quarter of 2026, payable on September 10 to shareholders recorded by August 14. This dividend reflects the company's ongoing commitment to returning value to shareholders amid...
BioArctic has entered a research collaboration with Eli Lilly to develop a new neurodegenerative disease treatment using BioArctic's BrainTransporter technology combined with a Lilly drug candidate. BioArctic will receive $30 million upfront and coul...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
Eli Lilly reported a 55.5% revenue increase in Q1 to $19.8 billion, led by $8.66 billion from Mounjaro, and raised its full-year revenue guidance to $82-$85 billion. Despite strong fundamentals, the stock has been stuck near $1,100 due to concerns ov...
